4β-methyl-5-(3-hydroxyphenyl)morphan opioid agonist and partial agonist derived from a 4β-methyl-5-(3-hydroxyphenyl)morphan pure antagonist

Journal of Medicinal Chemistry

Volumn 56, Issue 21, 2013, Pages 8826-8833

  Carroll, F Ivy ^a   Gichinga, Moses G ^a   Williams, John D ^a   Vardy, Eyal ^b   Roth, Bryan L ^b   Mascarella, S Wayne ^a   Thomas, James B ^a   Navarro, Hernán A ^a  

^a RTI INTERNATIONAL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 [3 (PROPAN 2 YLOXY)PHENYL] 2 AZABICYCLO[3.3.1]NONANE; 3 [4 METHYL 2 (3 PHENYLPROPYL) 2 AZABICYCLO [3.3.1]NON 5 YL]PHENOL; 4 METHYL 5 [3 (PROPAN 2 YLOXY)PHENYL] 2 AZABICYCLO[3.3.1]NONANE; 5 (3 HYDROXYPHENYL) 4 METHYL 2 (3 PHENYLPROP 1 YL) 7 PROPYLAMINO 2 AZABICYCLO[3.3.1]NONANE; 5 (3 HYDROXYPHENYL) 4 METHYL 7 METHYLAMINO 2 (3 PHENYLPROP 1 YL) 2 AZABICYCLO[3..3.1]NONANE; 7 (N CYCLOPROPYLMETHYLAMINO) 5 (3 HYDROXYPHENYL) 4 METHYL 2 (3 PHENYLPROP 1 YL) 2 AZABICYCLO[3.3.1]NONANE; 7 (N CYCLOPROPYLMETHYLMETHYLAMINO) 5 (3 HYDROXYPHENYL) 4 METHYL 2 (3 PHENYLPROP 1 YL) 2 AZABICYCLO[3.3.1]NONANE; 7 (N ETHYLMETHYLAMINO) 5 (3 HYDROXYPHENYL) 4 METHYL 2 (3 PHENYLPROP 1 YL) 2 AZABICYCLO[3.3.1]NONANE; 7 DIMETHYLAMINO 5 (3 HYDROXYPHENYL) 4 METHYL 2 (3 PHENYLPROP 1 YL) 2 AZABICYCLO[3.3.1]NONANE; 7 ETHYLAMINO 5 (3 HYDROXYPHENYL) 4 METHYL 2 (3 PHENYLPROP 1 YL) 2 AZABICYCLO[3.3.1]NONANE; 7 FORMYLAMINO 5 (3 HYDROXYPHENYL) 4 METHYL 2 (3 PHENYLPROP 1 YL) 2 AZABICYCLO[3.3.1]NONANE; N PHENYLPROPYL 4BETA METHYL 5 [3 (PROPAN 2 YLOXY)PHENYL] MORPHAN; OPIATE AGONIST; OPIATE ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; BINDING ASSAY; DRUG CONFORMATION; DRUG EFFICACY; DRUG POTENCY; ENANTIOMER;

AZABICYCLO COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MOLECULAR STRUCTURE; RECEPTORS, OPIOID; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84887855069     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401250s     Document Type: Article

References (27)

1. Zimmerman, D. M.; Nickander, R.; Horng, J. S.; Wong, D. T. New structural concepts for narcotic antagonists defined in a 4-phenylpiperidine series Nature 1978, 275, 332-334
2. Mitch, C. H.; Leander, J. D.; Mendelsohn, L. G.; Shaw, W. N.; Wong, D. T.; Cantrell, B. E.; Johnson, B. G.; Reel, J. K.; Snoddy, J. D.; Takemori, A. E.; Zimmerman, D. M. 3,4-Dimethyl-4-(3-hydroxyphenyl)piperidines: Opioid antagonists with potent anorectant activity J. Med. Chem. 1993, 36, 2842-2850
3. Thomas, J. B.; Mascarella, S. W.; Rothman, R. B.; Partilla, J. S.; Xu, H.; McCullough, K. B.; Dersch, C. M.; Cantrell, B. E.; Zimmerman, D. M.; Carroll, F. I. Investigation of the N-substituent conformation governing potency and mu receptor subtype-selectivity in (+)-(3R, 4R)-dimethyl-4-(3- hydroxyphenyl)piperidine opioid antagonists J. Med. Chem. 1998, 41, 1980-1990
4. Zimmerman, D. M.; Gidda, J. S.; Cantrell, B. E.; Schoepp, D. D.; Johnson, B. G.; Leander, J. D. Discovery of a potent, peripherally selective trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonist for the treatment of gastrointestinal motility disorders J. Med. Chem. 1994, 37, 2262-2265
5. Zimmerman, D. M.; Leander, J. D.; Cantrell, B. E.; Reel, J. K.; Snoddy, J.; Mendelsohn, L. G.; Johnson, B. G.; Mitch, C. H. Structure-activity relationships of the trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine antagonists for μ and κ opioid receptors J. Med. Chem. 1993, 36, 2833-2841
6. Carroll, F. I. 2002 Medicinal Chemistry Division Award address: monoamine transporters and opioid receptors. Targets for addiction therapy J. Med. Chem. 2003, 46, 1775-1794
7. Casy, A. F.; Dewar, G. H.; Al-Deeb, O. A. A. Stereochemical studies of the 4-alkyl-4-arylpiperidine class of opioid ligand Magn. Reson. Chem. 1989, 27, 964-972
8. Delaney, C. P.; Yasothan, U.; Kirkpatrick, P. Alvimopan Nat. Rev. Drug Discovery 2008, 7, 727-728
9. Leslie, J. B. Alvimopan: a peripherally acting mu-opioid receptor antagonist Drugs Today 2007, 43, 611-625
10. Statnick, M. A.; Suter, T. M.; Gackenheimer, S. L.; Emmerson, P. J.; Quimby, S. J.; Gehlert, D. R.; Wheeler, W. J.; Mitch, C. H. Na+-dependent high affinity binding of [3H]LY515300, a 3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid receptor inverse agonist Eur. J. Pharmacol. 2003, 482, 139-150
11. Beardsley, P. M.; Howard, J. L.; Shelton, K. L.; Carroll, F. I. Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats Psychopharmacology (Berl., Ger.) 2005, 183, 118-126
12. Jackson, K. J.; Carroll, F. I.; Negus, S. S.; Damaj, M. I. Effect of the selective kappa-opioid receptor antagonist JDTic on nicotine antinociception, reward, and withdrawal in the mouse Psychopharmacology (Berl., Ger.) 2010, 285-294
13. Knoll, A. T.; Meloni, E. G.; Thomas, J. B.; Carroll, F. I.; Carlezon, W. A., Jr. Anxiolytic-Like Effects of κ-Opioid Receptor Antagonists in Models of Unlearned and Learned Fear in Rats J. Pharmacol. Exp. Ther. 2007, 323, 838-845
14. Knoll, A. T.; Muschamp, J. W.; Sillivan, S. E.; Ferguson, D.; Dietz, D. M.; Meloni, E. G.; Carroll, F. I.; Nestler, E. J.; Konradi, C.; Carlezon, W. A., Jr. Kappa Opioid Receptor Signaling in the Basolateral Amygdala Regulates Conditioned Fear and Anxiety in Rats Biol. Psychiatry 2011, 70, 425-433
15. Nemeth, C. L.; Paine, T. A.; Rittiner, J. E.; Beguin, C.; Carroll, F. I.; Roth, B. L.; Cohen, B. M.; Carlezon, W. A., Jr. Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats Psychopharmacology (Berlin, Ger.) 2010, 210, 263-274
16. Thomas, J. B.; Zheng, X.; Mascarella, S. W.; Rothman, R. B.; Dersch, C. M.; Partilla, J. S.; Flippen-Anderson, J. L.; George, C. F.; Cantrell, B. E.; Zimmerman, D. M.; Carroll, F. I. N-Substituted 9β-methyl-5-(3- hydroxyphenyl)morphans are opioid receptor pure antagonists J. Med. Chem. 1998, 41, 4143-4149
17. Carroll, F. I.; Melvin, M. S.; Nuckols, M. C.; Mascarella, S. W.; Navarro, H. A.; Thomas, J. B. N-substituted 4β-methyl-5-(3-hydroxyphenyl)- 7α-amidomorphans are potent, selective kappa opioid receptor antagonists J. Med. Chem. 2006, 49, 1781-1791
18. Thomas, J. B.; Atkinson, R. N.; Namdev, N.; Rothman, R. B.; Gigstad, K. M.; Fix, S. E.; Mascarella, S. W.; Burgess, J. P.; Vinson, N. A.; Xu, H.; Dersch, C. M.; Cantrell, B. E.; Zimmerman, D. M.; Carroll, F. I. Discovery of an opioid kappa receptor selective pure antagonist from a library of N-substituted 4beta-methyl-5-(3-hydroxyphenyl)morphans J. Med. Chem. 2002, 45, 3524-3530
19. Carroll, F. I. Design and Development of Pharmacotherapies for Substance Abuse. 2006 Nathan B. Eddy Memorial Award Lecture; Proceedings of the 68th Annual Scientific Meeting of the College on Problems of Drug Dependence, National Institute on Drug Abuse: Bethesda, MD, 2007; pp 71-81.
20. Carroll, F. I.; Zhang, L.; Mascarella, S. W.; Navarro, H. A.; Rothman, R. B.; Cantrell, B. E.; Zimmerman, D. M.; Thomas, J. B. Discovery of the first N-substituted 4β-methyl-5-(3-hydroxyphenyl)morphan to possess highly potent and selective opioid delta receptor antagonist activity J. Med. Chem. 2004, 47, 281-284
21. Thomas, J. B.; Zhang, L.; Navarro, H. A.; Carroll, F. I. Highly potent and selective phenylmorphan-based inverse agonists of the opioid delta receptor J. Med. Chem. 2006, 49, 5597-5609
22. Carroll, F. I.; Chaudhari, S.; Thomas, J. B.; Mascarella, S. W.; Gigstad, K. M.; Deschamps, J.; Navarro, H. A. N-Substituted cis-4a-(3-hydroxyphenyl)-8a- methyloctahydroisoquinolines are opioid receptor pure antagonists J. Med. Chem. 2005, 48, 8182-8193
23. Roth, B. L.; Baner, K.; Westkaemper, R.; Siebert, D.; Rice, K. C.; Steinberg, S.; Ernsberger, P.; Rothman, R. B. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 11934-11939
24. Besnard, J.; Ruda, G. F.; Setola, V.; Abecassis, K.; Rodriguiz, R. M.; Huang, X. P.; Norval, S.; Sassano, M. F.; Shin, A. I.; Webster, L. A.; Simeons, F. R.; Stojanovski, L.; Prat, A.; Seidah, N. G.; Constam, D. B.; Bickerton, G. R.; Read, K. D.; Wetsel, W. C.; Gilbert, I. H.; Roth, B. L.; Hopkins, A. L. Automated design of ligands to polypharmacological profiles Nature 2012, 492, 215-220
25. Manglik, A.; Kruse, A. C.; Kobilka, T. S.; Thian, F. S.; Mathiesen, J. M.; Sunahara, R. K.; Pardo, L.; Weis, W. I.; Kobilka, B. K.; Granier, S. Crystal structure of the micro-opioid receptor bound to a morphinan antagonist Nature 2012, 485, 321-326
26. Wu, H.; Wacker, D.; Mileni, M.; Katritch, V.; Han, G. W.; Vardy, E.; Liu, W.; Thompson, A. A.; Huang, X. P.; Carroll, F. I.; Mascarella, S. W.; Westkaemper, R. B.; Mosier, P. D.; Roth, B. L.; Cherezov, V.; Stevens, R. C. Structure of the human kappa-opioid receptor in complex with JDTic Nature 2012, 485, 327-332
27. Surflex Dock, Sybyl-X, v. 2.1; Certara: St. Louis, MO, 2013.